These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23925946)

  • 1. A 12-week intramuscular toxicity study of risperidone-loaded microspheres in Beagle dogs.
    Tian J; Wang W; Ye L; Cen X; Guan X; Zhang J; Yu P; Du G; Liu W; Li Y
    Hum Exp Toxicol; 2014 May; 33(5):473-87. PubMed ID: 23925946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.
    Zhang J; Ye L; Wang W; Du G; Yu X; Zhu X; Dong Q; Cen X; Guan X; Fu F; Tian J
    Hum Exp Toxicol; 2015 Feb; 34(2):205-23. PubMed ID: 24812153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
    Tian J; Du G; Ye L; Yu X; Zhang J; Wang H; Yu P; Fu F; Liu W; Li Y; Cen X; Guan X
    Food Chem Toxicol; 2013 Feb; 52():143-52. PubMed ID: 23165154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
    An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
    Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD rats.
    Ye L; Guan X; Tian J; Zhang J; Du G; Yu X; Yu P; Cen X; Liu W; Li Y
    Food Chem Toxicol; 2013 Jun; 56():81-92. PubMed ID: 23454207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
    Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
    Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical review of a long-acting, injectable formulation of risperidone.
    Knox ED; Stimmel GL
    Clin Ther; 2004 Dec; 26(12):1994-2002. PubMed ID: 15823763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and safety profile of risperidone in a sample of children and adolescents.
    Margari L; Matera E; Craig F; Petruzzelli MG; Palmieri VO; Pastore A; Margari F
    Int Clin Psychopharmacol; 2013 Jul; 28(4):177-83. PubMed ID: 23689836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparation of ONO-1301-loaded poly(lactide-co-glycolide) microspheres and their effect on nerve conduction velocity.
    Hazekawa M; Sakai Y; Yoshida M; Haraguchi T; Morisaki T; Uchida T
    J Pharm Pharmacol; 2011 Mar; 63(3):362-8. PubMed ID: 21749383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone.
    Gomeni R; Heidbreder C; Fudala PJ; Nasser AF
    J Clin Pharmacol; 2013 Oct; 53(10):1010-9. PubMed ID: 23868656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.
    Ereshefsky L; Mascarenas CA
    J Clin Psychiatry; 2003; 64 Suppl 16():18-23. PubMed ID: 14680415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
    Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U
    J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres.
    Hu Z; Liu Y; Yuan W; Wu F; Su J; Jin T
    Colloids Surf B Biointerfaces; 2011 Aug; 86(1):206-11. PubMed ID: 21524893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.
    Hawley C; Turner M; Latif MA; Curtis V; Saleem PT; Wilton K
    Hum Psychopharmacol; 2010 Jan; 25(1):37-46. PubMed ID: 20041474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.